For example, Chen et al. [61] analysed changes in NLR among 101 advanced non-small cell lung cancer (NSCLC) patients undergoing therapy with programmed cell death 1 inhibitors. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.